1. Daily ingestion of the probiotic Lactobacillus paracasei ST11 decreases Vaccinia virus dissemination and lethality in a mouse model.
- Author
-
Dos Santos Pereira Andrade AC, Lima MT, Oliveira GP, Calixto RS, de Sales E Souza ÉL, da Glória de Souza D, de Almeida Leite CM, Ferreira JM, Kroon EG, de Oliveira DB, Dos Santos Martins F, and Abrahão JS
- Subjects
- Animals, Cytokines analysis, Disease Models, Animal, Eating, Inflammation therapy, Lung pathology, Lung virology, Male, Mice, Mice, Inbred BALB C, Lacticaseibacillus paracasei physiology, Probiotics, Vaccinia therapy, Vaccinia virus physiology
- Abstract
Vaccinia virus (VACV) is an important pathogen. Although studies have shown relationships between probiotics and viruses, the effect of probiotics on VACV infection is unknown. Therefore, this work aims to investigate the probiotics effects on VACV infection. Mice were divided into four groups, two non-infected groups, one receiving the probiotic, the other one not receiving it, and two groups infected intranasally with VACV Western Reserve (VACV-WR) receiving or not receiving the probiotic. Viral titres in organs and cytokine production in the lungs were analysed. Lung samples were also subjected to histological analysis. The intake of probiotic results in reduction in viral spread with a significant decrease of VACV titer on lung, liver and brain of treated group. In addition,treatment with the probiotic results in attenuated mice lung inflammation showing fewer lesions on histological findings and decreased lethality in mice infected with VACV. The ingestion of Lactobacillus paracasei ST11 (LPST11) after VACV infection resulted in 2/9 animal lethality compared with 4/9 in the VACV group. This is the first study on probiotics and VACV interactions, providing not only information about this interaction, but also proposing a model for future studies involving probiotics and other poxvirus.
- Published
- 2017
- Full Text
- View/download PDF